CA2725513C - Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer - Google Patents

Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer Download PDF

Info

Publication number
CA2725513C
CA2725513C CA2725513A CA2725513A CA2725513C CA 2725513 C CA2725513 C CA 2725513C CA 2725513 A CA2725513 A CA 2725513A CA 2725513 A CA2725513 A CA 2725513A CA 2725513 C CA2725513 C CA 2725513C
Authority
CA
Canada
Prior art keywords
nanoemulsion
component
perfluorcarbon
gene
genetic material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2725513A
Other languages
English (en)
French (fr)
Other versions
CA2725513A1 (en
Inventor
Soeren Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soluventis GmbH
Original Assignee
Soluventis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluventis GmbH filed Critical Soluventis GmbH
Publication of CA2725513A1 publication Critical patent/CA2725513A1/en
Application granted granted Critical
Publication of CA2725513C publication Critical patent/CA2725513C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2725513A 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer Active CA2725513C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156434A EP2123256A1 (en) 2008-05-19 2008-05-19 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
EP08156434.6 2008-05-19
PCT/EP2009/055779 WO2009141257A1 (en) 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Publications (2)

Publication Number Publication Date
CA2725513A1 CA2725513A1 (en) 2009-11-26
CA2725513C true CA2725513C (en) 2013-07-02

Family

ID=39869983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725513A Active CA2725513C (en) 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Country Status (14)

Country Link
US (1) US9616131B2 (https=)
EP (3) EP2123256A1 (https=)
JP (1) JP5546534B2 (https=)
CN (2) CN102847170B (https=)
AU (1) AU2009249812B2 (https=)
CA (1) CA2725513C (https=)
DK (2) DK2510921T3 (https=)
ES (2) ES2391375T3 (https=)
HU (1) HUE035320T2 (https=)
IL (1) IL209205A (https=)
NZ (1) NZ589417A (https=)
PL (2) PL2510921T3 (https=)
WO (1) WO2009141257A1 (https=)
ZA (1) ZA201008274B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
US20140065223A1 (en) * 2011-03-31 2014-03-06 Jeanette Libera-Koerner Perfluorinated compounds for the non-viral transfer of nucleic acids
CN103263695B (zh) * 2013-05-17 2014-10-29 中国人民解放军第四军医大学 全氟三乙胺乳液与种子细胞复合的神经导管制备方法
CN103251980B (zh) * 2013-05-17 2014-07-02 中国人民解放军第四军医大学 全氟三丁胺与纤维蛋白水凝胶复合的神经导管制备方法
EP2853595A1 (en) 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
CN110177575B (zh) * 2016-12-01 2024-02-13 国立大学法人埼玉大学 药物递送系统用胞吞作用增强剂
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6050578B2 (ja) 1981-12-25 1985-11-09 日本スチレンペ−パ−株式会社 合成樹脂発泡体の製造法
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
PL323931A1 (en) * 1995-06-07 1998-04-27 Alliance Pharma Compositions of reversed emulsion of fluorine derivatives of hydrocarbons for use as drug delivering carriers
JP2001002592A (ja) 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
KR100872884B1 (ko) 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
WO2002007717A1 (en) * 2000-07-20 2002-01-31 Otkrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma 'perftoran' Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion
CA2452471C (en) 2001-07-10 2010-06-29 Michael N. Davidson Enhancement of transfection of dna into the liver
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Also Published As

Publication number Publication date
CN102847170A (zh) 2013-01-02
CN102112109B (zh) 2016-10-12
EP2285349B1 (en) 2012-07-11
PL2285349T3 (pl) 2012-12-31
HK1179533A1 (zh) 2013-10-04
PL2510921T3 (pl) 2017-12-29
DK2285349T3 (da) 2012-10-22
EP2510921A1 (en) 2012-10-17
HK1159479A1 (zh) 2012-08-03
IL209205A (en) 2015-08-31
ZA201008274B (en) 2012-02-29
EP2510921B1 (en) 2017-07-12
WO2009141257A1 (en) 2009-11-26
ES2391375T3 (es) 2012-11-23
CA2725513A1 (en) 2009-11-26
JP2011520936A (ja) 2011-07-21
CN102847170B (zh) 2016-03-16
NZ589417A (en) 2012-03-30
AU2009249812A1 (en) 2009-11-26
IL209205A0 (en) 2011-01-31
EP2285349A1 (en) 2011-02-23
AU2009249812B2 (en) 2013-08-22
HUE035320T2 (en) 2018-05-02
US20110091561A1 (en) 2011-04-21
DK2510921T3 (en) 2017-10-23
CN102112109A (zh) 2011-06-29
US9616131B2 (en) 2017-04-11
JP5546534B2 (ja) 2014-07-09
EP2123256A1 (en) 2009-11-25
ES2642316T3 (es) 2017-11-16

Similar Documents

Publication Publication Date Title
CA2725513C (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
Huang et al. The landscape of mRNA nanomedicine
JP7600208B2 (ja) 拘束された脂質を含むナノ材料およびその使用
Hackett et al. Fatty acids as therapeutic auxiliaries for oral and parenteral formulations
He et al. Recent development of poly (ethylene glycol)-cholesterol conjugates as drug delivery systems
ES2711669A1 (es) Sistemas de liberacion de farmacos de acido polisialico y metodos
CN116270534A (zh) 一种组织选择性递送核酸药物的类脂质纳米颗粒及其制备方法和应用
WO2018096057A1 (en) Particles comprising surfactant protein b and one or more lipids
He et al. Diverse nanoparticles deliver mRNA to enhance tumor immunotherapy
CN120531894A (zh) 一种脂质纳米载体、药物制剂及制备方法和应用
CN120303251A (zh) 可电离脂质
EP4349328A1 (en) Lipoprotein-mimicking solid lipid nanoparticles for drug delivery and uses thereof
CN118695875A (zh) 在用于治疗和/或预防疾病的方法中使用的制剂
KR20200072471A (ko) 약학적 제제의 전달 조성물 및 방법
HK1159479B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
HK1179533B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
EP4268851A1 (en) Composition for preventing or treating cancer, containing lipid nanoparticles
Salunkhe et al. Oral Delivery of Lipid Nanosystem: Pharmacokinetics and Pharmacodynamic Advances
EP4540392A1 (en) Targeted nanomedicine for treating fibrotic lung disorders
Huang Functionalized Lipid Nanoparticles Show Efficacy in Glioma Animal Models
TW202541786A (zh) 脂質奈米顆粒
Dahiya Oral administration of mRNA-LNP therapeutics
WO2026090590A1 (en) Nanoparticle formulations for the delivery of dna to adipose tissue

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241115